Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 16/20 | 0.55 |
| ▸ | MKNK2 | Q9HBH9 | 15/20 | 0.55 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.45 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4903027 | 0.80 | OGA (0.47) | AKT3CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL4906864 | 0.79 | MKNK1 (0.71) | MKNK1MKNK2KCNH3CCNT1CCNA2 | |
| SCHEMBL2280012 | 0.78 | DNM2 (0.47) | MKNK1AKT3KCNH3 | |
| SCHEMBL4905848 | 0.73 | MKNK1 (0.66) | MKNK1MKNK2KCNH3CCNT1CCNA2 | |
| SCHEMBL12423188 | 0.72 | IKBKB (0.47) | AKT3CDK2CDK9 | |
| SCHEMBL18803536 | 0.71 | MKNK1 (1.00) | MKNK1MKNK2CCNT1CCNA2CDK2 | |
| SCHEMBL3645075 | 0.71 | MKNK1 (0.60) | MKNK1MKNK2KCNH3CCNT1CCNA2 | |
| SCHEMBL28133994 | 0.70 | HPGD (0.59) | MKNK1MKNK2KCNH3 | |
| SCHEMBL27665966 | 0.70 | AKT3 (0.64) | MKNK1MKNK2AKT3CCNT1CCNA2 | |
| SCHEMBL5006020 | 0.69 | AKT3 (0.78) | AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287452-A1 | HETEROARYL/ARYL PYRIMIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2008-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287452-A1 | HETEROARYL/ARYL PYRIMIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WNT3A, CTNNB1, WNT1 | MKNK1 682/4885MKNK2 701/4885AKT3 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.